evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

1,793 questions · 1,866 findings · 339 reviews

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 245 · 13.1%GRADE not reported 142 · 7.6%Very low 612 · 32.8%Low 513 · 27.5%Moderate 305 · 16.3%High 49 · 2.6%

Intervention not reported

Pain intensity various scales short‐term · adults with chronic low‐back pain
1 finding from 1 review

Levomepromazine vs Typical antipsychotics

Behaviour: Leaving the study early (short‐term) · patients with schizophrenia

Levomepromazine showed no clear difference in leaving the study early ‐ short term ‐ any reason compared with typical antipsychotics (low certainty).

1 finding from 1 review

Levomepromazine vs atypical antipsychotics

Leaving the study early ‐ short term ‐ due to lack of efficacy · patients with schizophrenia

It is very uncertain whether levomepromazine changes leaving the study early ‐ short term ‐ due to lack of efficacy compared with atypical antipsychotics (very low certainty).

1 finding from 1 review

Levomepromazine vs atypical antipsychotics

Leaving the study early ‐ short term ‐ due to patient deterioration · patients with schizophrenia

Levomepromazine showed no clear difference in leaving the study early ‐ short term ‐ due to patient deterioration compared with atypical antipsychotics (moderate certainty).

1 finding from 1 review

Levomepromazine vs atypical antipsychotics

Leaving the study early ‐ short term ‐ lost to · patients with schizophrenia

Levomepromazine showed no clear difference in leaving the study early ‐ short term ‐ lost to compared with atypical antipsychotics (low certainty).

1 finding from 1 review

Levomepromazine vs Typical antipsychotics

Leaving the study early ‐ short term ‐ due to lack of efficacy · patients with schizophrenia

Levomepromazine showed no clear difference in leaving the study early ‐ short term ‐ due to lack of efficacy compared with typical antipsychotics (low certainty).

1 finding from 1 review

Levomepromazine vs Typical antipsychotics

Withdrawals due to adverse events · patients with schizophrenia

Levomepromazine showed no clear difference in leaving the study early ‐ short term ‐ due to adverse events compared with typical antipsychotics (low certainty).

1 finding from 1 review

Levomepromazine vs atypical antipsychotics

Behaviour: Leaving the study early (short‐term) · patients with schizophrenia

Levomepromazine showed no clear difference in leaving the study early ‐ short term ‐ any reason compared with atypical antipsychotics (low certainty).

1 finding from 1 review

Levomepromazine vs atypical antipsychotics

Withdrawals due to adverse events · patients with schizophrenia

Levomepromazine showed no clear difference in leaving the study early ‐ short term ‐ due to adverse events compared with atypical antipsychotics (moderate certainty).

1 finding from 1 review

SULPIRIDE AUGMENTATION OF ANY ANTIPSYCHOTIC DRUG vs antipsychotics

Global state: 1. General ‐ no clinically significant improvement ‐ short term < 30% improvement on BPRS · patients with schizophrenia

SULPIRIDE AUGMENTATION OF ANY ANTIPSYCHOTIC DRUG showed no clear difference in global state: No clinically important response ‐ short term compared with ANY ANTIPSYCHOTIC DRUG (low certainty).

1 finding from 1 review

SULPIRIDE AUGMENTATION OF ANY ANTIPSYCHOTIC DRUG vs antipsychotics

Adverse events: Movement disorder ‐ any extra pyramidal symptoms ‐ short term · patients with schizophrenia

It is very uncertain whether SULPIRIDE AUGMENTATION OF ANY ANTIPSYCHOTIC DRUG changes specific adverse effects: 1a. CNS ‐ short term ‐ movement disorder ‐… compared with ANY ANTIPSYCHOTIC DRUG (very low certainty).

1 finding from 1 review

SULPIRIDE AUGMENTATION OF ANY ANTIPSYCHOTIC DRUG vs antipsychotics

Adverse events: Specific: Weight gain ‐ all doses of depot risperidone ‐ short term Spontaneous reporting by study participants · patients with schizophrenia

SULPIRIDE AUGMENTATION OF ANY ANTIPSYCHOTIC DRUG may leads to lower specific adverse effects: 3a. Endocrine system ‐ short term ‐ weight… compared with ANY ANTIPSYCHOTIC DRUG (low certainty).

1 finding from 1 review

SULPIRIDE AUGMENTATION OF ANY ANTIPSYCHOTIC DRUG vs antipsychotics

Specific adverse effects: 4. Gastrointestinal system ‐ short term ‐ salavation ‐ too much · patients with schizophrenia

SULPIRIDE AUGMENTATION OF ANY ANTIPSYCHOTIC DRUG may leads to lower specific adverse effects: 4. Gastrointestinal system ‐ short term ‐… compared with ANY ANTIPSYCHOTIC DRUG (low certainty).

1 finding from 1 review